Peptide LocalCompare price, evidence & access
Search /Compare vendors
Locations/South Africa/Retatrutide
Purchase and availability checkRetatrutide in South Africa

Can you buy Retatrutide in South Africa?

No legitimate retail purchase is established by the current records. Lilly says retatrutide is investigational, is not available for public use, and is legally available only through Lilly clinical trials.

Direct answers →Open official records →Open the interactive status check
Evidence lane
Lilly investigational status and SAHPRA supply warning
Destination
South Africa
Source records
3
Reviewed
24 July 2026
ByPeptide Local Editorial DeskUpdated 24 July 2026How we review
Direct answers

What this exact search can and cannot establish.

Each answer stays attached to the compound identity and destination records. This is a verification guide, not medical or legal advice, a seller recommendation, or proof of availability.

01

Can you buy Retatrutide in South Africa?

No legitimate retail purchase is established by the current records. Lilly says retatrutide is investigational, is not available for public use, and is legally available only through Lilly clinical trials. SAHPRA has warned about unregistered peptide products and has identified products sold under the retatrutide name in South African enforcement information. A website, local price, vial image, or delivery claim does not establish an authorized product. Check the exact product registration, seller identity, and supply route in the official records below.

02

Which official records should be checked for Retatrutide in South Africa?

Resolve the exact identity of Retatrutide through TRIUMPH-1 Phase 3 study - NCT05929066 from ClinicalTrials.gov. Then search Medicines Online Directory from South African Health Products Regulatory Authority for the destination product record and Pharmaceutical establishment licensing from South African Health Products Regulatory Authority for the seller, establishment, or supply route in South Africa. A match in one record does not replace the other two checks.

03

Does an online listing prove Retatrutide is authorized or available in South Africa?

No. A page using the name Retatrutide, local currency, a domestic delivery claim, or a familiar package image is only a lead. This is an investigational program, not an approved product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, or regulatory status. For South Africa, the exact product, presentation, seller identity, current record status, and claimed supply route must resolve through the official sources on this page.

Live trial footprint

Retatrutide clinical trials in South Africa

The current registry snapshot contains no Retatrutide study record with a listed South Africa location. This is a dated search result, not proof that a study cannot be added later.

Registry update: 24 July 2026
Study records
0
Listed locations
0
Recruiting locations
0
Records with local recruiting sites
0
0

The current registry snapshot contains no Retatrutide study record with a listed South Africa location. This is a dated search result, not proof that a study cannot be added later.

ClinicalTrials.gov search
Continue the exact comparison

Related country and compound records.

Compare another tracked name in South Africa, or keep Retatrutide fixed and change the destination within Middle East and Africa. The identity, product, and seller checks remain separate.

Continue the exact comparison

Retatrutide in Middle East and Africa

Retatrutide across 42 countries
Identity before availability

A name alone cannot establish a local verdict.

Lilly states that retatrutide is investigational, is not available for public use, and is legally available only through Lilly clinical trials. SAHPRA's public warning identifies products sold under the retatrutide name among falsified or unauthorized GLP-1 agonist products found in the South African market. Neither a seller listing nor a familiar name establishes an authorized product. The exact product record, seller identity, and supply route must be checked through current SAHPRA sources.

Primary identity source: TRIUMPH-1 Phase 3 study - NCT05929066 / ClinicalTrials.gov ↗
Three-record verification path

Identity. Product. Seller or supply.

A credible result must keep these separate. The official links answer different questions and should be checked in sequence.

TRIUMPH-1 Phase 3 study - NCT05929066

TRIUMPH-1 Phase 3 study - NCT05929066 is maintained by ClinicalTrials.gov. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.

Open TRIUMPH-1 Phase 3 study - NCT05929066 ↗

Medicines Online Directory

Medicines Online Directory is maintained by South African Health Products Regulatory Authority. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.

Open Medicines Online Directory ↗

Pharmaceutical establishment licensing

Pharmaceutical establishment licensing is maintained by South African Health Products Regulatory Authority. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.

Open Pharmaceutical establishment licensing ↗
South Africa / Country guide

South Africa market context.

SAHPRA currently names several peptides promoted through online platforms, social media, gyms, wellness centres, and informal suppliers. A product name, research label, local address, or laboratory report cannot replace the exact medicine and establishment records.

  • SAHPRA's current warning says unregistered peptide products are being unlawfully marketed in South Africa and names multiple peptides commonly promoted online.
  • The Medicines Online Directory covers SAHPRA-registered over-the-counter and prescription medicines and supports searches by medicine name or active ingredient.
  • SAHPRA's pharmaceutical register includes active, revoked, suspended, cancelled, and permanently closed establishments, so current status and legal identity both matter.
Destination checklist

Repeat the country checks before comparing any offer.

The country guide supplies the local verification sequence. It does not convert an online listing into an authorized product or verified seller.

01

Read the peptide-specific warning

Start with SAHPRA's public peptide page, which specifically addresses BPC-157, TB-500, CJC-1295, ipamorelin, PT-141, AOD-9604, Selank, Semax, Melanotan II, and certain GLP-1 products.

02

Search the medicine record

Use SAHPRA's Medicines Online Directory and registered-health-product resources to match the exact medicine, active ingredient, holder, pack, and current information instead of relying on a shared peptide name.

03

Verify the operating establishment

Check SAHPRA's pharmaceutical establishment register for the named manufacturer, importer, wholesaler, or distributor. A product entry and an establishment licence answer separate questions.

Primary evidence

Audit every source used by this page.

Open the live record and confirm its current status. A linked source begins the verification process; it does not mean Peptide Local authenticated a product or seller.

01
TRIUMPH-1 Phase 3 study - NCT05929066ClinicalTrials.gov
02
SAHPRA registered product information serviceSouth African Health Products Regulatory Authority
03
Pharmaceutical establishment licensingSouth African Health Products Regulatory Authority
04
What to know about retatrutideEli Lilly and Company
05
SAHPRA position on falsified and unauthorized GLP-1 agonist productsSouth African Health Products Regulatory Authority
06
Peptide Products public informationSouth African Health Products Regulatory Authority
07
Retatrutide study search in South AfricaClinicalTrials.gov
Audit and handoff

Keep the exact record attached.